← Back to Search

Surveillance Strategies for Lung Cancer(WTS Trial)

N/A

Waitlist Available

Led By Michael K Gould, MD, MS

Research Sponsored by Kaiser Permanente

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

at least one nodule measuring ≤15 mm in average diameter on chest CT.

Be older than 18 years old

Must not have

Be younger than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Upup to 4 years

Awards & highlights

No Placebo-Only Group

WTS Trial Summary

This trial will compare two different protocols for follow-up imaging of small pulmonary nodules discovered on chest CT scans.

Eligible Conditions

Solitary Pulmonary Nodule
Pulmonary Lesion
Lung Cancer
Non-Small Cell Lung Cancer

WTS Trial Eligibility Criteria

Inclusion Criteria

You will be eligible if you check “Yes” for the criteria below

WTS Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 4 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 4 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 4 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Malignant Neoplasms

Secondary outcome measures

Anxiety, measured with the State Anxiety Inventory, 6-item

Fetal Distress

Exposure to ionizing radiation, using the computed tomography dose index (CTDIvol), measured in mGy (milliGray)

+6 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

WTS Trial Design

2Treatment groups

Active Control

Group I: More Frequent CT SurveillanceActive Control1 Intervention

Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)

Group II: Less Frequent CT SurveillanceActive Control1 Intervention

Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.

0 / 1Eligibility criteria met

Find a Location

Who is running the clinical trial?

Kaiser PermanenteLead Sponsor

528 Previous Clinical Trials

23,759,390 Total Patients Enrolled

Patient-Centered Outcomes Research InstituteOTHER

534 Previous Clinical Trials

29,919,419 Total Patients Enrolled

University of California, DavisOTHER

895 Previous Clinical Trials

4,993,243 Total Patients Enrolled

Media Library

More Frequent CT Surveillance Clinical Trial Eligibility Overview. Trial Name: NCT02623712 — N/A

Solitary Pulmonary Nodule Research Study Groups: More Frequent CT Surveillance, Less Frequent CT Surveillance

Solitary Pulmonary Nodule Clinical Trial 2023: More Frequent CT Surveillance Highlights & Side Effects. Trial Name: NCT02623712 — N/A

More Frequent CT Surveillance 2023 Treatment Timeline for Medical Study. Trial Name: NCT02623712 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the main goals of this clinical experiment?

"This two-year long clinical trial aims to evaluate the prevalence of T1a stage or greater cancerous nodules according to AJCC staging system (7th edition). Secondary objectives involve assessing survival time from date of diagnosis, days between identification and diagnosis, and radiation exposure as measured by mGy (milliGray) CTDIvol."

Answered by AI

Are there any recruitment opportunities available for this trial?

"According to clinicaltrials.gov, this study is no longer recruiting participants after having first been posted on March 6th 2017 and its most recent update occurring on September 30th 2022. Nevertheless, 1932 other medical studies are presently seeking potential candidates for their trials."

Answered by AI